{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:54:25Z","timestamp":1791078865405,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Sherry L. Anderson CTCL Research"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.clml.2014.09.013","type":"journal-article","created":{"date-parts":[[2014,10,5]],"date-time":"2014-10-05T16:41:51Z","timestamp":1412527311000},"page":"e83-e93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Long-Term Complete Responses to Combination Therapies and Allogeneic Stem Cell Transplants in\u00a0Patients With S\u00e9zary Syndrome"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5650-6180","authenticated-orcid":false,"given":"Maxim","family":"Polansky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakhshandra","family":"Talpur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Daulat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitra","family":"Hosing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bouthaina","family":"Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Duvic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2014.09.013_bib1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1067\/mjd.2002.118538","article-title":"Update on erythrodermic cutaneous T-cell lymphoma: report on the International Society for Cutaneous Lymphomas","volume":"46","author":"Vonderheid","year":"2002","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clml.2014.09.013_bib2","first-page":"254","article-title":"Erythrodermie avec pr\u00e9sence de cellules monstrueuses dans le derme et le sang circulant","volume":"45","author":"S\u00e9zary","year":"1938","journal-title":"Bull Soc Fr Dermatol Syphiligr"},{"key":"10.1016\/j.clml.2014.09.013_bib3","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood.V66.2.358.358","article-title":"Diagnostic and prognostic significance of S\u00e9zary cells in peripheral blood smears from patients with cutaneous T cell lymphoma","volume":"66","author":"Vonderheid","year":"1985","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.013_bib4","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0190-9622(99)70057-5","article-title":"T-cell receptor gene analysis in the diagnosis of S\u00e9zary syndrome","volume":"41","author":"Russel-Jones","year":"1999","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clml.2014.09.013_bib5","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.013_bib6","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1182\/blood-2005-10-4239","article-title":"Significance of circulating T-cell clones in S\u00e9zary syndrome","volume":"107","author":"Ortonne","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.013_bib7","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/archdermatol.2011.232","article-title":"High clinical response rate of S\u00e9zary syndrome to immunomodulatory therapies","volume":"147","author":"Raphael","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clml.2014.09.013_bib8","first-page":"1234","article-title":"Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action","volume":"8","author":"Zhang","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2014.09.013_bib9","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/sj.jidsp.5640188","article-title":"Photopheresis: clinical application and mechanism of action","volume":"4","author":"Rook","year":"1999","journal-title":"J\u00a0Investig Dermatol Symp Proc"},{"key":"10.1016\/j.clml.2014.09.013_bib10","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2009.25.8301","article-title":"Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and S\u00e9zary syndrome","volume":"28","author":"Duvic","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.09.013_bib11","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1034\/j.1600-0609.2003.00143.x","article-title":"Treatment of patients with advanced mycosis fungoides and S\u00e9zary syndrome with alemtuzumab","volume":"71","author":"Kennedy","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2014.09.013_bib12","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1432-2277.2006.00382.x","article-title":"Different mechanisms of campath-1H-mediated depletion for CD4 and CD8 T cells in peripheral blood","volume":"19","author":"Lowenstein","year":"2006","journal-title":"Transpl Int"},{"key":"10.1016\/j.clml.2014.09.013_bib13","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1200\/JCO.1999.17.10.3117","article-title":"Pentostatin therapy of T-cell lymphomas with cutaneous manifestations","volume":"1","author":"Kurzrock","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.09.013_bib14","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1023\/A:1008377724139","article-title":"Pentostatin in T-cell malignancies\u2014a phase II trial of the EORTC: Leukemia Cooperative Group","volume":"10","author":"Ho","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2014.09.013_bib15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/PPO.0b013e31803c73cc","article-title":"Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy","volume":"13","author":"Piekarz","year":"2007","journal-title":"Cancer J"},{"key":"10.1016\/j.clml.2014.09.013_bib16","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.09.013_bib17","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1517\/13543784.16.7.1111","article-title":"Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma","volume":"16","author":"Duvic","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clml.2014.09.013_bib18","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.013_bib19","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1309\/U1Y6-J4AG-5M4M-7AYV","article-title":"Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood","volume":"115","author":"Jones","year":"2001","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2014.09.013_bib20","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1182\/blood.V100.9.3369","article-title":"Clonal heterogeneity in mycosis fungoides and its relationship to clinical course","volume":"100","author":"Vega","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.013_bib21","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-4632.2009.03771.x","article-title":"Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma","volume":"48","author":"Vidulich","year":"2009","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clml.2014.09.013_bib22","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1148\/74.4.633","article-title":"A\u00a0technique for large-field, superficial electron therapy","volume":"74","author":"Karzmark","year":"1960","journal-title":"Radiology"},{"key":"10.1016\/j.clml.2014.09.013_bib23","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1084\/jem.20021726","article-title":"Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma","volume":"197","author":"Kari","year":"2003","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.clml.2014.09.013_bib24","doi-asserted-by":"crossref","first-page":"223.e1","DOI":"10.1016\/j.jaad.2013.08.033","article-title":"Primary cutaneous T-cell lymphoma (mycosis fungoides and S\u00e9zary syndrome): part II. Prognosis, management, and future directions","volume":"70","author":"Jawed","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clml.2014.09.013_bib25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/CCO.0b013e3283253190","article-title":"Update of treatment of cutaneous T-cell lymphoma","volume":"21","author":"Gardner","year":"2009","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clml.2014.09.013_bib26","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/annonc\/mdu231","article-title":"Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (mycosis fungoides and S\u00e9zary syndrome)","volume":"25","author":"Dummer","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2014.09.013_bib27","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-CC chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.09.013_bib28","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/j.1365-2133.2007.07901.x","article-title":"Extracorporeal photopheresis in combination with bexarotene in the treatment of mycosis fungoides and S\u00e9zary syndrome","volume":"156","author":"Tsirigotis","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clml.2014.09.013_bib29","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 5","key":"10.1016\/j.clml.2014.09.013_bib30","first-page":"45","article-title":"Photopheresis in the treatment of cutaneous T-cell lymphoma","volume":"88","author":"Knobler","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2014.09.013_bib31","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/cncr.22596","article-title":"Results of a phase II trial of oral bexarotene (Targretin) combined with interfereon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma","volume":"109","author":"Straus","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.09.013_bib32","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1365-2133.2009.09037.x","article-title":"Bexarotene therapy for mycosis fungoides and S\u00e9zary syndrome","volume":"160","author":"Abbott","year":"2009","journal-title":"Br J Dermatol"},{"issue":"suppl","key":"10.1016\/j.clml.2014.09.013_bib33","first-page":"27","article-title":"Treatment of S\u00e9zary syndrome with bexarotene after IFNalpha and methotrexate failure","volume":"26","author":"Bagot","year":"2008","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.clml.2014.09.013_bib34","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jaad.2007.12.016","article-title":"Total skin electron beam therapy may be associated with improvement of peripheral blood disease in S\u00e9zary syndrome","volume":"58","author":"Introcaso","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clml.2014.09.013_bib35","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jaad.2012.09.056","article-title":"Improvement in peripheral blood disease burden in patients with S\u00e9zary syndrome and leukemic mycosis fungoides after total skin electron beam therapy","volume":"68","author":"Klein","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clml.2014.09.013_bib36","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.11127","article-title":"Low-dose intermittent alemtuzumab in the treatment of S\u00e9zary syndrome: clinical and immunologic findings in 14 patients","volume":"92","author":"Berengo","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2014.09.013_bib37","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti CD-52 monoclonal antibody) in patients with advanced mycosis fungoides\/S\u00e9zary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.013_bib38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1046\/j.0902-4441.2004.00169.x","article-title":"Successful treatment of chemotherapy refractory S\u00e9zary syndrome with alemtuzumab (campath-1H)","volume":"72","author":"Gautschi","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2014.09.013_bib39","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.3109\/10428190903216770","article-title":"Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center","volume":"50","author":"Querfeld","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2014.09.013_bib40","first-page":"519","article-title":"Clinical studies of T-cell erythroderma in the S\u00e9zary syndrome","volume":"49","author":"Winkelmann","year":"1974","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2014.09.013_bib41","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1038\/sj.onc.1210380","article-title":"Alemtuzumab (campath-1H) in the treatment of chronic lymphocytic leukemia","volume":"26","author":"Alinari","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2014.09.013_bib42","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood.V96.2.685.014k26_685_690","article-title":"Expression pattern of T-cell-associated chemokine receptors and their chemokine correlates with specific subtypes of T-cell non-Hodgkin lymphoma","volume":"96","author":"Jones","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.013_bib43","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-04-0371","article-title":"CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified","volume":"10","author":"Ishida","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2014.09.013_bib44","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/01.pas.0000213267.92349.59","article-title":"Chemokine receptor expression in cutaneous T cell and NK\/T-cell lymphomas: immunohistochemical staining and in\u00a0vitro chemotactic assay","volume":"30","author":"Yagi","year":"2006","journal-title":"Am J Surg Pathol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014004236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014004236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:26:01Z","timestamp":1761870361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265014004236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S2152265014004236"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2014.09.013","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Complete Responses to Combination Therapies and Allogeneic Stem Cell Transplants in\u00a0Patients With S\u00e9zary Syndrome","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2014.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}